Literature DB >> 15848056

Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations.

Carmen Calinescu1, Jérôme Mulhbacher, Eric Nadeau, John Morris Fairbrother, Mircea Alexandru Mateescu.   

Abstract

Carboxymethyl high amylose starch (CM-HAS) is proposed as a novel excipient for oral tablet formulation of bioactive agents ensuring their protection in the stomach and delivery in the intestine. Three variants of CM-HAS, with different degrees of substitution, were synthesized by starch treatment with various amounts of monochloroacetic acid. The products were dried in powder form and tablets were obtained by direct compression of mixed powders of polymeric excipient and lyophilized Escherichia coli (E. coli) bacteria. Dosage forms of CM-HAS are unswollen and compact in acidic medium, ensuring protection of active agents against acidity. Release of bacteria from CM-HAS tablets is based on the fast swelling of the tablets during the passage from gastric acidity to alkaline intestinal medium, enzymatic hydrolysis triggering their rapid, almost total dissolution. The bacteria thus formulated displayed higher survival rates in acidic gastric conditions and for longer periods than the free bacteria or than the bacteria formulated with the non-derivatized starch. The CM-HAS selected matrix also assured a good viability of bacteria after 6 months under refrigeration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848056     DOI: 10.1016/j.ejpb.2004.12.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

Review 1.  A review of the advancements in probiotic delivery: Conventional vs. non-conventional formulations for intestinal flora supplementation.

Authors:  Mershen Govender; Yahya E Choonara; Pradeep Kumar; Lisa C du Toit; Sandy van Vuuren; Viness Pillay
Journal:  AAPS PharmSciTech       Date:  2013-09-25       Impact factor: 3.246

2.  Influence of drying procedure and of low degree of substitution on the structural and drug release properties of carboxymethyl starch.

Authors:  Marc Lemieux; Patrick Gosselin; Mircea Alexandru Mateescu
Journal:  AAPS PharmSciTech       Date:  2010-05-05       Impact factor: 3.246

3.  Development of probiotic tablets using microparticles: viability studies and stability studies.

Authors:  J P Sousa e Silva; Sérgio C Sousa; Paulo Costa; Emília Cerdeira; Maria H Amaral; José Sousa Lobo; Ana M Gomes; Maria M Pintado; Dina Rodrigues; Teresa Rocha-Santos; Ana C Freitas
Journal:  AAPS PharmSciTech       Date:  2012-12-12       Impact factor: 3.246

4.  Carboxymethyl starch/alginate microspheres containing diamine oxidase for intestinal targeting.

Authors:  Lindsay Blemur; Tien Canh Le; Lucia Marcocci; Paola Pietrangeli; Mircea Alexandru Mateescu
Journal:  Biotechnol Appl Biochem       Date:  2015-06-29       Impact factor: 2.431

5.  Design of Catalase Monolithic Tablets for Intestinal Targeted Delivery.

Authors:  Mirna Alothman; Pompilia Ispas-Szabo; Mircea Alexandru Mateescu
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

6.  An Attenuated Escherichia coli K88ac LT(S63K)ΔSTb Efficiently Provides Protection Against Enterotoxigenic Escherichia coli in the Mouse Model.

Authors:  Xinyu Zhang; Shupei Yu; Darong Cheng; Yu Feng; Yuefei Yang; Huaichang Sun; Jiabo Ding; Fang Wang
Journal:  Front Vet Sci       Date:  2021-02-12

7.  Synthesis and evaluation of the structural and physicochemical properties of carboxymethyl pregelatinized starch as a pharmaceutical excipient.

Authors:  Sonia Lefnaoui; Nadji Moulai-Mostefa
Journal:  Saudi Pharm J       Date:  2015-02-04       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.